- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/40 - 2,5-Pyrrolidine-diones
Patent holdings for IPC class C07D 207/40
Total number of patents in this class: 138
10-year publication summary
|
5
|
13
|
14
|
13
|
6
|
5
|
5
|
5
|
7
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Alkermes Pharma Ireland Limited | 254 |
16 |
| Cv6 Therapeutics (NI) Limited | 33 |
10 |
| Hangzhou DAC Biotech Co., Ltd | 113 |
5 |
| Uniwersytet Jagiellonski | 278 |
4 |
| Warszawski Uniwersytet Medyczny | 65 |
4 |
| Allergan, Inc. | 2162 |
3 |
| Chevron Oronite Company LLC | 593 |
3 |
| Mainstream Pine Products, LLC | 59 |
3 |
| Novartis AG | 10251 |
2 |
| The Regents of the University of California | 20778 |
2 |
| Syngenta Participations AG | 1516 |
2 |
| Hewlett-Packard Development Company, L.P. | 25180 |
2 |
| University of Southern California | 2134 |
2 |
| Afton Chemical Corporation | 498 |
2 |
| Dana-Farber Cancer Institute, Inc. | 2665 |
2 |
| Instituto Mexicano Del Petroleo | 201 |
2 |
| ISP Investments Inc. | 440 |
2 |
| Iteos Therapeutics | 18 |
2 |
| Janssen Sciences Ireland UC | 155 |
2 |
| Korea University Research and Business Foundation | 3271 |
2 |
| Other owners | 66 |